The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Ropes & Gray LLP

Work +1 617 951 7000
Boston, Central Hong Kong, Chicago, East Palo Alto, London EC4A, London EC4M and 6 more

Paul Kinsella

Ropes & Gray LLP


Paul represents companies in business combinations, securities offerings, and corporate governance matters. Examples of 2015 M&A transactions include advising: •Cubist in its sale to Merck for $9.5 billion. • Pfizer in its pending acquisition of Hospira for approximately $17 billion. •Wright Medical in its pending merger of equals with Tornier. Examples of 2015 securities offerings include advising: •Wright Medical in a $632.5 million convertible note offering. •Novavax in a $201.25 million equity offering. • Akebia in a $65 million equity offering.

United States: Finance

Capital markets: equity offerings

Within: Capital markets: equity offerings

Ropes & Gray LLP boosted its capital markets team in 2016 through the hires of New York-based securities partner Michael Littenberg from Schulte Roth & Zabel LLP, and San Francisco-based counsel Jesse Cuevas from Shearman & Sterling LLP. The group had a strong year, acting on a string of debut and follow-on offerings and secondary offerings. In a high-profile cross-border deal, life sciences specialist Marc Rubenstein acted alongside the firm’s Hong Kong office in advising Hutchinson China MediTech on its $101m IPO. Among its work for underwriters, practice co-head Patrick O’Brien acted for the lead underwriters in two separate follow-on offerings for Sage Therapeutics totaling $325m. David Fine, Julie Jones and department co-head Paul Kinsella are also recommended. Named partners are based in Boston except where otherwise stated.

[back to top]

United States: M&A/corporate and commercial

M&A: large deals ($1bn+)

Within: M&A: large deals ($1bn+)

Ropes & Gray LLP has a ‘strong team with great skills and knowledge that is totally dedicated to the process and outcome’. The firm is praised for its life sciences expertise and for its consistent ability to assemble a ‘functioning team with different skills and areas of expertise’ that delivers ‘an aligned and seamless service’. Over the last few years, the firm has managed to develop a hugely impressive strategic M&A practice alongside its longstanding position as a private equity buyouts heavyweight. The life sciences, pharmaceutical and healthcare sectors continue to be its forte. Recent work includes advising Shire Pharmaceuticals on its headline $32bn acquisition of Baxalta, a deal which involved significant tax complexities and regulatory issues connected to Shire being a Jersey incorporated company that has an Irish tax domicile and is listed in London and on Nasdaq. The firm also advised Shire on its $6.5bn acquisition of biotech company Dyax. Jane Goldstein is co-head of the M&A group and splits her time between New York and Boston. Christopher Comeau has an exceptional record in high-value life sciences transactions. Julie Jones has an impressive mix of private equity and corporate relationships and Paul Kinsella is noted for life sciences and medical technology transactions. John Sorkin provides additional senior level credibility in the New York office, where he is also noted for representing financial advisers. New York-based Othon Prounis and Carl Marcellino are also strong in M&A and private equity. In February 2017, Paul Scrivano joined the firm's San Francisco office from O’Melveny & Myers LLP as global head of M&A.All named partners are based in Boston unless stated otherwise.

[back to top]

Back to index

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to